| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| systematic review | Q1504425 |
| review article | Q7318358 |
| P50 | author | Susana Perez-Gutthann | Q88611465 |
| Andrea V Margulis | Q41066288 | ||
| P2093 | author name string | Silvana Romio | |
| Brian Calingaert | |||
| Manel Pladevall | |||
| Lorna Hazell | |||
| Cristina Varas-Lorenzo | |||
| Nuria Riera-Guardia | |||
| P2860 | cites work | Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations | Q22241134 |
| Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Q22241288 | ||
| Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review | Q22242077 | ||
| A meta-analysis of the association between adherence to drug therapy and mortality | Q24548922 | ||
| Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies | Q24632655 | ||
| Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study | Q24652963 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting | Q27861077 | ||
| Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus | Q28297680 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| Marginal structural models and causal inference in epidemiology | Q29619287 | ||
| Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis | Q30975674 | ||
| Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research | Q30980766 | ||
| Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). | Q31120403 | ||
| Development of the RTI item bank on risk of bias and precision of observational studies | Q33454018 | ||
| Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank | Q33456912 | ||
| Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. | Q33527739 | ||
| Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis | Q34056132 | ||
| Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data | Q34099031 | ||
| Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone | Q34123137 | ||
| Rosiglitazone: a European regulatory perspective. | Q34154718 | ||
| Evaluating Medication Effects Outside of Clinical Trials: New-User Designs | Q52956338 | ||
| Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) | Q57245141 | ||
| Thiazolidinediones and Heart Failure: A teleo-analysis | Q57413498 | ||
| Database Evaluation of the Effects of Long-Term Rosiglitazone Treatment on Cardiovascular Outcomes in Patients With Type 2 Diabetes | Q61850097 | ||
| The prognosis of heart failure in the general population: The Rotterdam Study | Q74243270 | ||
| Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study | Q80728031 | ||
| Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin | Q85197540 | ||
| A new "Comparative Effectiveness" assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone | Q85197950 | ||
| Management of comorbid diabetes mellitus and worsening heart failure | Q88097851 | ||
| Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies. | Q34315902 | ||
| ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the | Q34640762 | ||
| Predictors of incident heart failure in a large insured population: a one million person-year follow-up study | Q35040761 | ||
| Pioglitazone initiation and subsequent hospitalization for congestive heart failure | Q36570644 | ||
| Improved survival after heart failure: a community-based perspective | Q36974231 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Insulin resistance--mechanisms, syndromes, and implications | Q37278330 | ||
| Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study | Q37310162 | ||
| Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. | Q37460057 | ||
| Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. | Q37995132 | ||
| Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. | Q38091002 | ||
| Cardiac consequences of diabetes mellitus | Q40476564 | ||
| Licensing drugs for diabetes | Q42916316 | ||
| Risk of Cardiovascular Events and All-Cause Mortality in Patients Treated With Thiazolidinediones in a Managed-Care Population | Q42927058 | ||
| Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan | Q42979688 | ||
| Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan | Q43588086 | ||
| Glycemic control and heart failure among adult patients with diabetes | Q43628822 | ||
| Immortal time bias in observational studies of drug effects | Q44123059 | ||
| Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study | Q44255319 | ||
| Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy | Q44433534 | ||
| Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study | Q44631747 | ||
| Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortality. | Q44818088 | ||
| Metformin therapy and prognosis of patients with heart failure and new-onset diabetes mellitus. A propensity-matched study in the community | Q45180627 | ||
| Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication | Q45227350 | ||
| Evaluating the potential benefits of metformin in patients with cardiovascular disease and heart failure | Q45236977 | ||
| Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes | Q45330821 | ||
| Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study | Q45723372 | ||
| Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study. | Q46002806 | ||
| The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy | Q46525578 | ||
| Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population | Q46720277 | ||
| Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study | Q46721366 | ||
| Thiazolidinediones and cardiovascular outcomes in older patients with diabetes | Q46855431 | ||
| European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constitute | Q48525600 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | carbohydrate | Q11358 |
| urea | Q48318 | ||
| heart failure | Q181754 | ||
| heterocyclic compound | Q193430 | ||
| anti-diabetic medication | Q575062 | ||
| systematic review | Q1504425 | ||
| thiazoles | Q2420555 | ||
| type 2 diabetes | Q3025883 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 129 | |
| P577 | publication date | 2014-09-26 | |
| P1433 | published in | BMC Cardiovascular Disorders | Q15753126 |
| P1476 | title | The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies | |
| P478 | volume | 14 |
| Q36960633 | A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes |
| Q49503081 | Are physicians neglecting the risk of heart failure in diabetic patients who are receiving sulfonylureas? Lessons from the TOSCA.IT trial |
| Q38857056 | Cardiovascular effects of anti-diabetes drugs |
| Q35894680 | Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies |
| Q37011769 | Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations |
| Q48188587 | Clinical impact of oral antidiabetic medications in heart failure patients. |
| Q38829782 | Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study |
| Q33815573 | Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure |
| Q33660548 | Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study. |
| Q47691659 | Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial |
| Q38967994 | Emerging drugs for the treatment of angina pectoris. |
| Q64097205 | Evaluation of in vivo antidiabetic, antidyslipidemic and in vitro antioxidant activities of hydromethanolic root extract of Datura stramonium L. (Solanaceae) |
| Q26801170 | Glycemia Lowering and Risk for Heart Failure: Recent Evidence from Studies of Dipeptidyl Peptidase Inhibition |
| Q35415945 | LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD). |
| Q35976501 | Letter: Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database (Diabetes Metab J 2015;39:247-52). |
| Q99252369 | Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials |
| Q36531654 | Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications? |
| Q58804870 | Pioglitazone Induces Cardiomyocyte Apoptosis and Inhibits Cardiomyocyte Hypertrophy Via VEGFR-2 Signaling Pathway |
| Q42379243 | Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials |
| Q40166604 | Pioglitazone-induced congestive heart failure and pulmonary edema in a patient with preserved ejection fraction |
| Q36765350 | Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. |
| Q35976506 | Response: Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database (Diabetes Metab J 2015;39:247-52). |
| Q92184218 | Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both? |
Search more.